(Q40487397)

21 September 2017

1 reference

title

Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues (English)

1 reference

21 September 2017

1 reference

F Kamali

1

1 reference

21 September 2017

publication date

1 May 1993

1 reference

Journal of Molecular Medicine

21 September 2017

published in

1 reference

21 September 2017

volume

71

1 reference

21 September 2017

issue

5

1 reference

21 September 2017

page(s)

392-405

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00186630

21 September 2017

exact match

0 references

cites work

Kaposi's sarcoma: an oncologic looking glass

1 reference

12 December 2020

Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects

1 reference

12 December 2020

Failure of zidovudine prophylaxis after exposure to HIV-I

1 reference

12 December 2020

Pharmacokinetics and bioavailability of zidovudine in humans

1 reference

12 December 2020

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity

1 reference

12 December 2020

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis

1 reference

12 December 2020

1 reference

12 December 2020

Neurologic disorders associated with HIV infections

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

1 reference

12 December 2020

Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus

1 reference

12 December 2020

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

1 reference

12 December 2020

Possible zidovudine-induced hepatotoxicity

1 reference

12 December 2020

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

1 reference

12 December 2020

3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents

1 reference

12 December 2020

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

1 reference

12 December 2020

Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine

1 reference

12 December 2020

Is AIDS dementia due to increases in calcium?

1 reference

12 December 2020

The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides

1 reference

12 December 2020

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

1 reference

12 December 2020

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

1 reference

12 December 2020

Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine

1 reference

12 December 2020

Natural history of HIV infection

1 reference

12 December 2020

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

1 reference

12 December 2020

Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group

1 reference

12 December 2020

Use of beta 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection

1 reference

12 December 2020

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

1 reference

12 December 2020

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex

1 reference

12 December 2020

Nail and mucocutaneous hyperpigmentation with azidothymidine therapy

1 reference

12 December 2020

Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus seropositive individuals

1 reference

12 December 2020

Interferon-alpha and 3'-azido-3'-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

1 reference

12 December 2020

Kaposi's sarcoma. IV. Detection of CMV DNA, CMV RNA and CMNA in tumor biopsies

1 reference

12 December 2020

Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells

1 reference

12 December 2020

Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses

1 reference

12 December 2020

Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases

1 reference

12 December 2020

Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid

1 reference

12 December 2020

Zidovudine update: 1990.

1 reference

12 December 2020

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

12 December 2020

Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal

1 reference

12 December 2020

Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides

1 reference

12 December 2020

Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study

1 reference

12 December 2020

Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men

1 reference

12 December 2020

Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

1 reference

12 December 2020

Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age.

1 reference

12 December 2020

AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex

1 reference

12 December 2020

Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus

1 reference

12 December 2020

The AIDS dementia complex: I. Clinical features

1 reference

12 December 2020

Effects of 2?,3?-dideoxynucleosides on mammalian cells and viruses

1 reference

12 December 2020

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort

1 reference

12 December 2020

Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex

1 reference

12 December 2020

Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

1 reference

12 December 2020

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

1 reference

12 December 2020

Metabolism of 2',3'-dideoxyinosine (ddI) in human blood

1 reference

12 December 2020

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

12 December 2020

Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

1 reference

12 December 2020

Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial

1 reference

12 December 2020

Only temporary improvement in impaired neuropsychological function in AIDS patients treated with zidovudine

1 reference

12 December 2020

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

1 reference

12 December 2020

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

1 reference

12 December 2020

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

12 December 2020

Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

1 reference

12 December 2020

Developmental therapeutics and the acquired immunodeficiency syndrome

1 reference

12 December 2020

Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells

1 reference

12 December 2020

Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations

1 reference

12 December 2020

Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report

1 reference

12 December 2020

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

12 December 2020

Characterization of the acute clinical illness associated with human immunodeficiency virus infection

1 reference

12 December 2020

Treatment of human immunodeficiency virus-infected infants and young children with dideoxynucleosides

1 reference

12 December 2020

Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial

1 reference

12 December 2020

Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro

1 reference

12 December 2020

Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine

1 reference

12 December 2020

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

1 reference

12 December 2020

Predicting who will progress to AIDS.

1 reference

12 December 2020

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

1 reference

12 December 2020

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

1 reference

12 December 2020

Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study

1 reference

12 December 2020

Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine

1 reference

12 December 2020

The Acquired Immunodeficiency Syndrome

1 reference

12 December 2020

Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections

1 reference

12 December 2020

Transfer of zidovudine (AZT) by human placenta

1 reference

12 December 2020

3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion

1 reference

12 December 2020

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

1 reference

12 December 2020

Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction

1 reference

12 December 2020

Failure of zidovudine to maintain remission in patients with AIDS.

1 reference

12 December 2020

In Vivo Additive Antiretroviral Effect of Combined Zidovudine and Foscarnet Therapy for Human Immunodeficiency Virus Infection (ACTG Protocol 053)

1 reference

12 December 2020

Quantitation of human immunodeficiency virus type 1 in the blood of infected persons

1 reference

12 December 2020

Recombinant human erythropoietin for patients with AIDS treated with zidovudine

1 reference

12 December 2020

Strategies for antiviral therapy in AIDS.

1 reference

12 December 2020

Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity

1 reference

12 December 2020

Follow-up of neuropathy from 2',3'-dideoxycytidine

1 reference

12 December 2020

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

12 December 2020

Zidovudine after occupational exposure to HIV

1 reference

12 December 2020

Influence of probenecid and paracetamol (acetaminophen) on zidovudine glucuronidation in human liver in vitro

1 reference

12 December 2020

Mitochondrial myopathy caused by long-term zidovudine therapy

1 reference

12 December 2020

Zidovudine intolerance.

1 reference

12 December 2020

Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)

1 reference

12 December 2020

Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy

1 reference

12 December 2020

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

1 reference

12 December 2020

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00186630

1 reference

21 September 2017

1 reference